ClinicalTrials.Veeva

Menu

"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program" (HALT-AD)

A

Alzheimer's Disease Cooperative Study (ADCS)

Status

Completed

Conditions

Alzheimer's Disease
Dementia Prevention
Dementia

Treatments

Behavioral: HALT-AD

Study type

Interventional

Funder types

Other

Identifiers

NCT05350410
HALT-AD

Details and patient eligibility

About

A Pilot Study for the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program (HALT-AD). This initial four-months pilot study will focus on at least three educational courses (introduction to dementia and lifestyle risk factors, sleep and diet). It may also include a fourth educational course on social connectivity and loneliness. Completion of this initial pilot study will allow for a round of improvements informed by data from the program, on usability, as well as feedback from participants and citizen advisors. This will allow for an iterative process to build the program to its full content, with feedback to optimize the user experience and ensure the accessibility of the content. The information generated from this study will help inform the development of the second program's prototype, expected to benefit from the initial pilot to become more user-friendly, effective and accessible to the target audience.

This pilot study will be a longitudinal study of an inception cohort exposed to the HALT-AD online educational program for a four-month study. It will utilize pre- and post- intervention collection of quantitative and qualitative data to evaluate the program's first prototype.

Full description

Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program (HALT- AD) is a novel bilingual educational program that will focus on reducing risk factors with the ultimate goal of preventing dementia. It will be centered around a web-based interactive virtual online platform that will be developed to be dynamic, engaging, and interactive. Through interactive courses, the educational content of HALT-AD will provide guidance on modifiable lifestyle risk factors and the identification of treatable medical conditions including cerebrovascular health, sleep, sensory loss, social isolation, mood, diet, and physical activity.

Participants in HALT-AD will be provided with personalized risk profiles, will be encouraged to learn about risk factors and how they can effectively modify them, and will be provided with feedback on their progress. Participants will participate in facilitated support discussion groups, which will focus on the content of the educational material and the invocation of change through participant engagement and compliance.

Prior to launching the full HALT-AD program, it is essential that the Sponsor conduct a preliminary pilot study to evaluate the program's first prototype. At the end of the 3-month pilot program, evaluations will include: the usability of- and engagement with- the online platform and users' acceptability of the learning content and facilitated support discussion groups. As well as evaluating preliminary evidence on the effectiveness of the program in changing knowledge, self-efficacy, and dementia-related lifestyle risk factors. The program will also be evaluated on metrics such as being user friendly, engaging, supportive and communicative, with the potential for scalability to state- and national-levels.

Aims:

  1. To evaluate engagement with- the online platform

  2. To evaluate preliminary evidence on the effectiveness of the program in changing

    a) knowledge, b) self-efficacy, and c) dementia-related lifestyle risk factors

  3. To determine users' acceptability of the program content

  4. To determine users' acceptability and satisfaction with the facilitated support discussion groups

  5. To evaluate the usability of the online platform

Enrollment

20 patients

Sex

All

Ages

50 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Signed informed consent must be obtained and documented (from the participant).
  2. Sufficient proficiency in English or Spanish to undergo clinical assessment and participate in an online educational program.
  3. Ages 50-85
  4. Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22
  5. Technical ability to participate in an online educational program (i.e. ability to operate a computer/tablet and gain internet access; ability to send and receive emails)
  6. Sufficient vision and hearing to participate in online educational program (judgement of site investigator)
  7. Ability to sit comfortably for a period of at least 30 minutes

Exclusion criteria

  1. Participants who, in the opinion of the co-PIs, are not able to complete trial procedures or adhere to the schedule of study assessments will be excluded from study participation.
  2. Individuals where English or Spanish is not sufficiently proficient for clinical assessment, and participation in a web-based educational program.
  3. Participants who do not have sufficient vision and hearing to participate in an online educational program
  4. Individuals who do not have the technical ability to participate in an online educational program. Technical ability is defined as ability to operate a computer/tablet and gain internet access; ability to send and receive emails)
  5. Total Score on the T-MoCA <18
  6. Individuals who have an advanced degree (e.g. Master's, MD, PhD) in an area related to brain health will not be eligible to participate.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

HALT-AD
Experimental group
Description:
HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
Treatment:
Behavioral: HALT-AD

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems